Today's Date: March 28, 2024
Government of Canada signs two bilateral agreements with Quebec to support initiatives to improve health care   •   Avnos and Deep Sky Forge Path to Gigaton-Scale Carbon Removal in Canada   •   The Lenserf Group Launches Emotional Intelligence Academy for HBCU Interns   •   Lenzing strives to drive beneficial transformation across the value chain   •   Stora Enso publishes Green and Sustainability-Linked Financing Report 2023   •   Lightshift Energy Raises $100 Million From Greenbacker Capital Management to Expand Utility Scale Battery Storage Across North A   •   Chris Diehl Returns to 101 Mobility as Director of National Accounts   •   3EO Health Announces the First Point of Care Molecular Test Under $15   •   Clean Energy Appoints Patrick J. Ford to Board of Directors   •   Fox Lake Grade School District 114 Selects Varsity Tutors for Schools to Provide Students with Additional Learning Resources   •   Cardinal Tobin Blesses New Open-Air Mausoleum of the Holy Spirit Site   •   Ministry of Education and Science of Ukraine and Palantir Partner to Create Safe Conditions for In-Person Education in Schools   •   Apogee Enterprises Schedules Fourth Quarter Fiscal Year 2024 Earnings Release and Conference Call   •   Parental avoidance of toxic exposures could help prevent autism, ADHD in children, new study shows   •   Latest U.S. Soybean Field Trials by Texas Crop Science Deliver Average Yield Increase of More Than 20%   •   Guo Guangchang: "Focus on building sustainable, predictable and enterprise with stable profit growth "   •   Netcracker Continues Its Support of the U.S. Paralympic Ski and Snowboard Team at Adaptive Spirit 2024   •   PRIVATE SCHOOL VILLAGE (PSV) AWARDS INAUGURAL ELEMENTARY-SCHOOL SCHOLARSHIPS   •   The Home Depot Announces Agreement to Acquire SRS Distribution, a Leading Specialty Trade Distributor Across Multiple Verticals;   •   Nutrex-Hawaii Introduces Its #1 Selling BioAstin® Hawaiian Astaxanthin® in a Retail-Ready, Sugar-Free, Vegan Gummy Forma
Bookmark and Share

Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff

BOSTON , December 05 /Businesswire/ - Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on December 5, 2022, Spectrum’s Board of Directors granted an aggregate of 736,988 inducement restricted stock units (“RSUs”) to commercial non-executive employees who were hired specifically for the launch of ROLVEDON. The awards were granted under Spectrum’s 2022 Employment Inducement Incentive Award Plan (“Inducement Plan”) as employment inducement awards pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spectrum, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Spectrum, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over three years on the first three anniversaries of the grant date, subject to continued service through each applicable vesting date.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a pipeline with novel assets that serve areas of unmet need. For additional information on Spectrum please visit www.sppirx.com.

Notice Regarding Forward-looking statements

This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including Spectrum's ability to successfully execute across the biopharmaceutical business model, including successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, the possibility that our commercialization efforts may not be successful, our dependence on third parties for manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™ and ROLVEDON™ are the Spectrum Pharmaceuticals’ logos and trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2022 Spectrum Pharmaceuticals, Inc. All Rights Reserved


STORY TAGS: Share Issue, United States, North America, Pharmaceutical, Health, Oncology, Biometrics, Massachusetts,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News